We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Study Explains Genetic Roots of Alzheimer's

By Biotechdaily staff writers
Posted on 25 Apr 2007
A study has uncovered a molecular mechanism that links the susceptibility gene to the process of Alzheimer's disease onset.

Scientists have known for more than a decade that individuals with a certain gene are at higher risk for developing Alzheimer's disease. More...
Now, a new study helps explain why this is so. The findings appear in the April 11, 2007, issue of The Journal of Neuroscience and may lead to new pathways for development of Alzheimer's therapeutics.

The research, led by scientists at the Oklahoma Medical Research Foundation (OMRF; www.omrf.org), has uncovered a molecular mechanism that links the susceptibility gene to the process of Alzheimer's disease onset. Approximately 15% of the population carries a gene that causes their bodies to produce a lipoprotein--a combination of fat and protein that transports lipids in the blood--known as apolipoprotein (Apo) E4. Studies have found that those who inherit the E4 gene from one parent are three times more likely than average to develop Alzheimer's, while those who get the gene from both parents have a tenfold risk of developing the disease.

In the new study, OMRF's Jordan J.N. Tang, Ph.D., and his colleagues discovered that ApoE4 attaches itself to a particular receptor on the surface of brain cells. That receptor, in turn, adheres to a protein known as amyloid precursor protein. The brain cells then transport the entire protein mass inside.

Once inside, cutting enzymes--called proteases--attack the amyloid precursor protein. These cuts create protein fragments that, when present in the brain for long periods of time, are believed to cause the cell death, memory loss, and neurologic dysfunction characteristic of Alzheimer's. Although researchers have known for more than a decade that ApoE4 was involved--somehow--in development of Alzheimer's, Dr. Tang's new study is the first to connect the process of protein fragment formation to ApoE4.

While roughly one in seven persons carry the E4 gene, the remainder of the population carries only two variations, E2 and E3, of that gene. These individuals have a markedly lower incidence of Alzheimer's than those who carry the E4 gene. The new study found that ApoE4 produced more protein fragments than did E2 or E3.

"ApoE4 apparently interacts better with the receptor than its cousins,” said Dr. Tang. "This may explain why people who carry the E4 gene have a higher risk of developing Alzheimer's. These findings may allow us to investigate the possibility of therapeutic intervention at different points in the process.” For example, he said, such efforts might focus on developing a compound to interfere with the receptor's ability to adhere to ApoE4. "There currently is no effective treatment for Alzheimer's disease, so we must explore every possible option to find a way to stop it,” he continued.

"Dr. Tang's study shows a beautiful biochemical connection between a genetic risk factor and the development of a disease,” said OMRF president Stephen Prescott, M.D. "This work opens the door to the development of alternate methods for treating--and perhaps even preventing--Alzheimer's.”


Related Links:
OMRF

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
POC Immunoassay Analyzer
Procise DX
New
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.